Form 4: AbbVie Executive Timothy J. Richmond Reports Stock Sales

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports the sale of AbbVie common stock in multiple transactions.

Summary

• Timothy J. Richmond, EVP and Chief HR Officer of AbbVie, filed a Form 4 detailing changes in beneficial ownership.
• On February 28, 2025, 16,904 shares were disposed of to cover tax obligations at a price of $205.02.
• On March 3, 2025, Richmond sold 5,677 shares at an average price of $209.8, 14,973 shares at an average price of $210.66, and 600 shares at an average price of $211.32.
• Following these transactions, Richmond directly owns 6,130 shares of AbbVie common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning or diversification. The sales themselves don't necessarily indicate a negative outlook for the company, but investors often monitor these transactions for insights into management's perspective.

Comparison to Industry Standards

• Executive compensation and stock ownership are closely watched metrics in the pharmaceutical industry.
• Comparing Richmond's transactions to those of executives at similar companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK) could provide context.
• Analyzing the percentage of shares sold relative to total holdings is a common practice.
• It's important to consider the vesting schedules of stock options and restricted stock units when evaluating executive stock sales.

Stakeholder Impact

• Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Sale, AbbVie, ABBV, Richmond, Executive Compensation